Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Plos One|June 24, 2014
Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01Jes Dietrich, Lars Vibe Andreasen, Peter Andersen, et al.
Expert Opinion on Drug Delivery|November 22, 2005
The MediChew technology platformBirgitte Hyrup, Carsten Andersen, Lars Vibe Andreasen, et al.
Vaccine|February 21, 2015
Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and ratsLars Vibe Andreasen, Lasse Bøllehuus Hansen, Peter Andersen, et al.
Journal of Liposome Research|June 12, 2009
Liposome-based cationic adjuvant formulations (CAF): past, present, and futureDennis Christensen, Else Marie Agger, Lars Vibe Andreasen, et al.
Vaccine|July 20, 2011
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01Anders Fomsgaard, Ingrid Karlsson, Gregers Gram, et al.
Clinical Immunology (Orlando, Fla.)|January 15, 2013
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infectionIngrid Karlsson, Lea Brandt, Lasse Vinner, et al.
AIDS Research and Human Retroviruses|May 3, 2013
Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-BissauVictor Raúl Gómez Román, Kristoffer Jarlov Jensen, Sanne Skov Jensen, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
Frontiers in Immunology|March 31, 2023
First in man study: Bcl-Xl_42-CAF<sup>®</sup>09b vaccines in patients with locally advanced prostate cancerSofie Kirial Mørk, Per Kongsted, Marie Christine Wulff Westergaard, et al.
Journal for Immunotherapy of Cancer|May 23, 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanomaSofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri, et al.
Pageof 1